In the current study, Titze and his colleagues 1 suggest that local hypertonicity is sensed by macrophages, which then produce the angiogenic protein vascular endothelial growth factor-C (VEGF-C). VEGF-C stimulates lymphatic vessel growth, creating a third fluid compartment that buffers the increased body Na + and volume and ameliorates the high blood pressure associated with excess salt intake ( Fig. 1) .
In studies of cultured macrophages, the authors showed that increased osmotic stress activates a transcription factor known to be activated in response to osmotic stress, tonicity enhanced binding protein (TonEBP), which, in turn, induces VEGF-C expression 1 . The authors also showed that this pathway is important in regulating blood pressure 1 . If it was blocked in rats by macrophage depletion or inhibition of VEGF-C signaling, blood pressure elevation was exacerbated.
Finally, the authors provide evidence that this pathway might be activated in humans by showing elevated circulating concentrations of VEGF-C in individuals with hypertension 1 . It is conceivable that defects in this pathway could result in redistribution of volume to the intravascular space, which could further elevate blood pressure.
Additional studies of this third fluid compartment are needed to further understand its impact on blood pressure regulation and volume homeostasis. One open question is how osmotically inactive Na + , such as that bound to proteoglycans, can induce a hypertonic state that can be sensed by adjacent cells such as macrophages. In this regard, the cell culture studies in which macrophages were exposed to high Na + concentrations in the medium might not reflect conditions in the in vivo subcutaneous interstitium, where the Na + is not free but supposedly bound to proteoglycans and thus osmotically inactive. Estimates of the absolute volume and electrolyte content of this subcutaneous interstitial compartment, although difficult to obtain, would be informative. For example, it would be useful to understand how various hypertensive states and antihypertensive drugs affect the distribution of fluid between the subcutaneous lymphatic compartment and the intravascular space. It is quite possible that this subcutaneous interstitial space is affected differently by high blood pressure of different causes, such as that caused by kidney disease, renovascular hypertension, excessive catecholamines or essential hypertension. It is also possible that the subset of the population predisposed to salt-sensitive hypertension may have a dysfunctional Na + buffering mechanism in the skin interstitium. The new findings might also explain why antiangiogenesis drugs that block VEGF signaling, commonly used for the treatment of cancer, often cause hypertension 6 .
Macrophages have a key role in innate immunity and are commonly viewed as evil doers in cardiovascular disease 7, 8 . The current findings suggest that macrophages can be beneficial in modulating salt-sensitive hypertension and that treatment strategies to inhibit macrophage function might be deleterious in this setting. Recent studies have implicated cells of the adaptive immune system, in particular T cells, in the pathogenesis of hypertension 9, 10 . These cells are transported by lymphatic vessels, and it is possible that they affect the ability of lymphatic vessels to modulate blood pressure. Moreover, there are crucial interactions between T cells and macrophages that could influence the ability of macrophages to participate in the pathway defined in the current study 11 .
The findings presented by Titze and his colleagues 1 and other recent studies emphasize the complexity of blood pressure regulation. These studies indicate that uniquely stored sodium, the skin subcutaneous lymphatic vessels and macrophages contribute to volume homeostasis and blood pressure control. Future challenges will be developing tools and applications to study the interactions between the skin interstitium and other organs, such as the kidney, What does it take to identify a gene that is crucial for the pathophysiology of schizophrenia? A genetic association replicated across several cohorts? Postmortem changes in the brains of diseased individuals? Gene effects on brain structure and cognitive processing? All of above, and some more.
The study by Huffaker et al. 1 in this issue of Nature Medicine has it all, providing compelling evidence that the KCNH2 gene, which encodes a membrane-spanning potassium channel, may be a strong contributor to the disease phenotype. Additionally, the authors show that KCNH2 has a role in cortical physiology, cognition and psychosis.
Schizophrenia is a devastating brain disorder characterized by abnormal mental functions and disturbed behavior 2 (Fig.  1) . Vulnerability to schizophrenia is clearly related to genetic factors. Yet, the inheritance of this complicated disease is nonmendelian, as alleles in multiple genes carry moderate to small effects in predisposing to the disease 3 . The genetic and genome-wide association studies in the last few decades have There are potentially important clinical implications to these findings. Although the genetic association of KCNH2 with schizophrenia is only modest (and comparable to that observed for other putative schizophrenia susceptibility genes), KCNH2 still deserves our full attention. We know that a good drug target does not have to show an exceptionally strong genetic signal: thiazolidinediones are potent type 2 diabetes treatment agents that target the gene encoding peroxisome proliferator-activated receptor gamma (PPARG), a gene that showed a less than impressive genetic association with diabetes 8 . Furthermore, it is also important to remember that the currently available antipsychotic treatments do not directly target genes that were identified by genetic observations. Consequently, we must not judge schizophrenia drug targets on the basis of the strength they show in genetic association studies-rather, we should use a 'converging evidence strategy' to prioritize them. It is also important to point out that KCNH2 is a membrane-inserted potassium ion channel and, owing to its expression on the cell surface, represents a more accessible drug target than the intracellular proteins 9 .
What is the natural continuation of these studies? The need for replication of the findings by other researchers is obvious, and there is also an apparent need for the expansion of the mechanistic studies related to KCNH2 regulation and function in the brain. Intriguingly, one might hypothesize that antipsychotic medications, directly or indirectly, can regulate the function of the KCNH2 gene. This hypothesis is based on the converging observations that KCNH2 is also expressed in heart muscle, mutations of the KCNH2 gene cause long QT syndrome type 2 (ref. 10) and 3 and that patients with schizophrenia who receive antipsychotic medication show increased QT interval on EKG 11 .
The pessimist can point out that this is a half-empty glass and that we are only at the initial stages of understanding the relationship of KCNH2 to schizophrenia. One might also argue that, despite the very promising initial observations, the road to drug development is always paved with numerous uncertainties 12 . However, there is also reason for optimism. The findings that KCNH2 has a prominent role in cortical physiology, cognition and psychosis suggest that this gene is a key piece of the schizophrenia puzzle and that this converging evidence strategy is promising for new drug target identification. After all, single-method discoveries did not deliver promising schizophrenia treatment candidates to date, and we must explore conceptually new approaches. mance, brain structure or postmortem gene expression. This is the arena where the work of Huffaker et al. 1 excels, as it provides a road map for how we should perform future studies.
The authors initially observed a diseaseassociated SNP near the KCNH2 gene transcription start site, located in the 7q36.1 chromosomal region. This was an intriguing but inconclusive observation on its own, and it had to be replicated, expanded and put into a pathophysiological context of the investigated disease.
To achieve this, the authors tested whether risk-associated SNPs affected the biology of the brain regions affected in schizophrenia 1 . First, they found that a particular variant of KCNH2, isoform 3.1, which arises from an alternate transcription start site near the risk-associated SNPs, was a primate-specific transcript not expressed in rodents 1 . Second, structural brain imaging studies revealed a notable volume decrease in the hippocampus of the individuals carrying the minor riskassociated alleles. Third, functional imaging studies discovered inefficient information processing in unaffected individuals carrying the risk-associated alleles. Fourth, riskassociated SNPs also predicted increased expression of the KCNH2 isoform 3.1 mRNA in the postmortem human hippocampus. Fifth, electrophysiological characterization of primary cortical neurons showed that overexpression of KCNH2 isoform 3.1 leads to profound changes in neuronal firing pattern.
identified several promising schizophrenia susceptibility genes (for example, disrupted in schizophrenia-1 (DISC1), neuregulin-1 (NRG1), regulator of G protein signaling-4 (RGS4) and dystrobrevin-binding protein-1 (DTNBP1)). It has been postulated that riskassociated polymorphisms interact with a wide range of environmental factors during a developmental time line 2 .
So, where do we stand today? Unfortunately, our understanding of the disease is still limited. Genetic studies of schizophrenia rarely show irrefutable disease association, are not easily replicated and are unable to provide mechanistic insight into the disease process 4, 5 . Postmortem studies are underpowered, complicated by the presence of other conditions, progression of pathology over time, treatment effects and postmortem changes in the brain tissue 6 . Animal models cannot recapitulate the complex genetics and environmental influences that are the core feature of the disorder 7 , whereas cognitive assessments and functional imaging studies fail to address the molecular mechanisms at work. In light of these serious limitations, what is the right strategy to arrive at the answers we seek?
The most promising (and perhaps only) strategy is to accept the limitations of each individual method and to seek convergence among various findings 5 . A weak genetic association is meaningless on its own, yet it becomes intriguing if the identified single nucleotide polymorphism (SNP) is associated with altered cognitive perfor- It's amazing that any of us has made it this far, let alone that any of our children are healthy. It's well known that high rates of abnormal chromosome segregation (nondisjunction) occur in human female meiosis, leading to chromosomal aneuploidy and early pregnancy loss or offspring with developmental disorders 1 . Studies of early human embryos after in vitro fertilization (IVF) have shown even higher rates of aneuploidy than those found in early pregnancy or at birth, a discrepancy that may be accounted for by pregnancies lost before their detection. Such embryos also have high rates of mosaic aneuploidy, meaning that only some early blastomeres have abnormal chromosome number-indicating that mitotic nondisjunction events are also common, at least in this in vitro environment [2] [3] [4] [5] [6] . Now, new microarray-based technologies reveal that structural chromosome abnormalities also occur at a shockingly high rate in early embryos. In this issue of Nature Medicine, Vanneste et al. 7 show that only 9% of IVF embryos have a normal karyotype in all blastomeres. The great majority show abnormalities of chromosome number or structure, such as large-scale duplications or deletions, or uniparental disomy, in which a chromosome pair is derived entirely from one parent. These abnormalities are often in mosaic form (Fig.  1) . The normal diploid blastomeres, outnumbered, have to battle for survival to allow normal embryonic development and birth.
This study was made possible by advances in microarray-based technologies that allow genome-wide assessment of copy number (deletions, duplications and aneuploidy) and single nucleotide polymorphisms (SNPs).
The authors used whole-genome bacterial artificial chromosome (BAC) arrays as well as improved statistical methods for accurate identification of copy number changes from the DNA of single blastomeres compared to normal reference samples. This technology is changing rapidly, with a host of wholegenome oligonucleotide, SNP and bead-chip formats now available for highly accurate copy number assessment in customizable formats [8] [9] [10] .
A key feature of the report by Vanneste et al. 7 is that they were able to study embryos from young, healthy couples with normal fertility (the couples were at risk for inherited genetic diseases unrelated to fertility). These embryos are the best representation of normal embryogenesis available for study in humans.
To determine baseline rates of meiotic aneuploidy and structural imbalances before mitotic cell division, the authors examined fertilized oocytes, which showed a low level of aneuploidy 7 . The picture was markedly different for the three-and four-day-old cleavagestage embryos, most at the eight cell stage: only 2 of 23 embryos showed completely normal results in all blastomeres tested (9%), whereas the majority showed abnormalities. Almost half of the embryos had no normal blastomeres at all! In contrast with studies of aneuploidy in pregnancy loss or liveborns, the authors found that mitotic nondisjunction was much more common than meiotic nondisjunction, as evidenced by mosaicism for aneuploid and diploid blastomeres or mosaicism for different (two maternal chromosome 15s) Figure 1 An eight-cell embryo illustrating the types of mosaicism reported in Vanneste et al. 7 . In addition to normal cells, there are mitotically derived aneuploidies (trisomy 7, monosomy 4 and uniparental disomy 15) and mitotic structural imbalances (deletion 4q and duplication 4q, which are reciprocal products of the same structural breakage event).
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